The stock of Lucid Diagnostics Inc (LUCD) has gone up by 9.13% for the week, with a 30.38% rise in the past month and a 23.35% rise in the past quarter. The volatility ratio for the week is 7.35%, and the volatility levels for the past 30 days are 5.71% for LUCD. The simple moving average for the past 20 days is 9.80% for LUCD’s stock, with a 11.54% simple moving average for the past 200 days.
Is It Worth Investing in Lucid Diagnostics Inc (NASDAQ: LUCD) Right Now?
Additionally, the 36-month beta value for LUCD is 1.42. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for LUCD is 19.02M and currently, short sellers hold a 2.22% ratio of that float. The average trading volume of LUCD on November 13, 2024 was 254.99K shares.
LUCD) stock’s latest price update
Lucid Diagnostics Inc (NASDAQ: LUCD)’s stock price has soared by 3.00 in relation to previous closing price of 1.00. Nevertheless, the company has seen a gain of 9.13% in its stock price over the last five trading days. prnewswire.com reported 2024-11-13 that EsoGuard® revenue up 20 percent sequentially Clinical evidence package for Medicare coverage submission complete Direct contracting initiative expanded to multiple programs to drive near-term revenue growth Conference call and webcast to be held today, November 13 th at 8:30 AM EST NEW YORK, Nov. 13, 2024 /PRNewswire/ — Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed”), today provided a business update for the Company and presented financial results for the three months ended September 30, 2024. Conference Call and Webcast The webcast will take place on Wednesday, November 13, 2024, at 8:30 AM and will be accessible in the investor relations section of the Company’s website at luciddx.com.
Analysts’ Opinion of LUCD
Many brokerage firms have already submitted their reports for LUCD stocks, with Ascendiant Capital Markets repeating the rating for LUCD by listing it as a “Buy.” The predicted price for LUCD in the upcoming period, according to Ascendiant Capital Markets is $16 based on the research report published on December 27, 2021 of the previous year 2021.
Needham, on the other hand, stated in their research note that they expect to see LUCD reach a price target of $17. The rating they have provided for LUCD stocks is “Buy” according to the report published on November 08th, 2021.
Cantor Fitzgerald gave a rating of “Overweight” to LUCD, setting the target price at $21 in the report published on November 08th of the previous year.
LUCD Trading at 19.69% from the 50-Day Moving Average
After a stumble in the market that brought LUCD to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -34.81% of loss for the given period.
Volatility was left at 5.71%, however, over the last 30 days, the volatility rate increased by 7.35%, as shares surge +28.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +30.39% upper at present.
During the last 5 trading sessions, LUCD rose by +10.19%, which changed the moving average for the period of 200-days by -25.71% in comparison to the 20-day moving average, which settled at $0.9383. In addition, Lucid Diagnostics Inc saw -26.95% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for LUCD
Current profitability levels for the company are sitting at:
- -9.98 for the present operating margin
- -0.44 for the gross margin
The net margin for Lucid Diagnostics Inc stands at -10.56. The total capital return value is set at -1.4. Equity return is now at value -300.52, with -121.82 for asset returns.
Based on Lucid Diagnostics Inc (LUCD), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -2.62. The debt to equity ratio resting at 2.06. The interest coverage ratio of the stock is 12077.69.
Currently, EBITDA for the company is -49.75 million with net debt to EBITDA at 0.12. When we switch over and look at the enterprise to sales, we see a ratio of -1.16. The receivables turnover for the company is 30.13for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.75.
Conclusion
In conclusion, Lucid Diagnostics Inc (LUCD) has seen mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
